<DOC>
	<DOCNO>NCT00779376</DOCNO>
	<brief_summary>The objective study ass single-dose relative bioavailability Ranbaxy GlaxoSmithKline ( Retrovir Â® ) 300 mg Zidovudine tablet , feed condition</brief_summary>
	<brief_title>Bioequivalence Study Zidovudine 300 mg Tablets , USP Under Fed Conditions</brief_title>
	<detailed_description>This open label , randomize , single dose , 2-way crossover , comparative bioavailability study perform 68 healthy adult volunteer . In period , subject house least 10 hour dose 12 hour blood draw . Single oral dose 300 mg Zidovudine dos separate washout period 7 day . A total sixty-eight ( 68 ) healthy adult subject ( 29 male 39 female ) enrol study , sixty five ( 65 ) subject ( 29 male 36 female ) complete clinical portion study .</detailed_description>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>1 . Healthy adult male female volunteer , 1855 year age 2 . Weighing least 52 kg male 45 kg female within 15 % ideal weight ( table 'Desirable weight Adults ' , Metropolitan Life Insurance Company , 1983 ) 3 . Medically healthy subject clinically normal laboratory profile , vital sign ECGs 4 . Females child bear potential either sexually inactive ( abstinent ) 14 day prior first dose throughout study use one follow acceptable birth control method : Surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum ; IUD place least 3 month ; Barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose throughout study Surgical sterilization partner ( vasectomy 6 month minimum ) Hormonal contraception least 3 month prior first dose study Other birth control method deem acceptable 5 . Postmenopausal woman amenorrhea least 2 year 6 . Given voluntary write informed consent participate study . 1 . History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic psychiatric disease 2 . In addition history presence alcoholism drug abuse within past year , hypersensitivity idiosyncratic reaction Zidovudine nucleoside analogue 3 . Female subject pregnant lactate 4 . Subjects test positive screening HIV , HBsAg HCV 5 . Subjects use drug substance know strong inhibitor cyp enzyme ( formerly know cytochrome p 450 enzyme ) within 10 day prior first dose 6 . Subjects use drug substance know strong inducer cyp enzyme ( formerly know cytochrome P 450 enzyme ) within 28 day prior first dose throughout study 7 . Subjects completion study would donate excess 500 mL blood 14 day , 1500 mL blood 180 day 2500 mL blood 1 year 8 . Subjects participate another clinical trial within 28 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>